Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Unicycive Achieves Primary Endpoint In Pivotal Bioequivalence Study Of Renazorb

  Renazorb demonstrates pharmacodynamic bioequivalence to Fosrenol   Renazorb's enhanced product profile features reduced pill burden and small, swallowable tablets, which may improve patient
byBenzinga Newsdesk
December 28, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

 

Renazorb demonstrates pharmacodynamic bioequivalence to Fosrenol
 

Renazorb’s enhanced product profile features reduced pill burden and small, swallowable tablets, which may improve patient compliance

On track to file New Drug Application mid-2023

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts